US Pharma MarketingPrivate Swiss biotechs hit record funding amid slowdown in public financing
Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion). | Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion). However, a relatively small pool of companies drove the funding jump while many of their peers raised nothing, echoing the global gap between the haves and have-nots. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy…
Funding for privately traded Swiss biotechs hit a new high last year, climbing 38% to 1.15 billion Swiss francs ($1.5 billion). However, a relatively small pool of companies drove the funding jump while many of their peers raised nothing, echoing the global gap between the haves and have-nots.
Source: FierceBiotech